Cancer-hunting antibodies coupled with a natural compound found in soil microbes proved a powerful combination against an ...

Lynozyfic (linvoseltamab) has been given accelerated approval by the US regulator for adults with relapsed or refractory ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

In February 2025 Harbour BioMed announced that the IND application for HBM9378 (SKB378), a TSLP-targeting monoclonal antibody ...

The companies place the partnership’s value at up to $1.5 billion, including an undisclosed up-front payment in the ...

Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...

Pfizer Inc. (PFE) on Thursday said that its therapy Hympavzi demonstrated improvement in bleeding outcomes for adults and ...

A cancer immunotherapy may slow Parkinson’s disease by blocking the spread of harmful brain proteins, Johns Hopkins researchers found.

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

In May, the company announced the failure of the monoclonal antibody birtamimab to improve mortality in a phase 3 trial of ...